• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 10, 2021 at 11:02: AM
via Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S.

article source
 

<



Similar threads

cafead
Sanofi and Regeneron&#039;s Dupixent scores in Europe as the first biologic to treat COPD
Replies
0
Views
70
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AbbVie&#039;s Rinvoq conquers Regeneron and Sanofi&#039;s Dupixent in eczema trial—again
Replies
0
Views
144
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi, Regeneron&#039;s Dupixent could hit $20B in peak sales with COPD expansion: analyst
Replies
0
Views
726
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sanofi and Regeneron&#039;s Dupixent scores trial win in tough-to-treat COPD
Replies
0
Views
184
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA Approves Regeneron-Sanofi&#039;s Sarilumab As First Biologic For Stiffness, Pain In Muscles
Replies
0
Views
239
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote